CIA
ADPT icon

CSat Investment Advisory’s Adaptive Biotechnologies ADPT Stock Holding History

CSat Investment Advisory’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-347
Closed -$17K – 527
2020
Q3 		$17K Buy
347
+43
+14% +$1.81K ﹤0.01% 907
2020
Q2 		$15K Buy
+304
New +$11.1K ﹤0.01% 913

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CSat Investment Advisory's ADPT Position: Q4 2020 in Review

CSat Investment Advisory sold out of Adaptive Biotechnologies (ADPT) in Q4 2020, closing a stake of 347 shares — an estimated $17K sold.

CSat Investment Advisory first reported a position in ADPT in Q2 2020 and held it in 2 quarters. The position peaked at $17K in Q3 2020. 250 funds tracked by Wall St. Rank hold ADPT as of Q4 2020.

  • CSat Investment Advisory reported no remaining Adaptive Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 347 Adaptive Biotechnologies shares in Q4 2020, an estimated $17K.
  • CSat Investment Advisory first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's Adaptive Biotechnologies position peaked at $17K in Q3 2020.
  • 250 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.